CytoSorbents Announces Resignation of Chief Financial Officer Alexander D’Amico
01 Septembre 2023 - 10:43PM
CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment
of life-threatening conditions in intensive care and cardiac
surgery using blood purification via its proprietary polymer
adsorption technology, announced that Alexander D’Amico has
resigned as the Company’s Chief Financial Officer as part of a
mutual termination and release agreement with the Company,
effective August 28, 2023.
As part of the agreement, CytoSorbents and Mr.
D’Amico have agreed to terminate his employment agreement with the
Company dated July 10, 2023 in its entirety, and have agreed to
customary and mutual non-disparagement and release provisions,
payment of specific accrued expenses, and no severance payments or
vesting of equity.
Ms. Kathleen Bloch will continue to serve as the
Company’s Interim Chief Financial Officer pursuant to the existing
consulting agreement arrangement between the Company and Ms.
Bloch.
About CytoSorbents Corporation (NASDAQ:
CTSO)
CytoSorbents Corporation is a leader in the
treatment of life-threatening conditions in the intensive care unit
and in cardiac surgery through blood purification. Its flagship
product, CytoSorb®, is approved in the European Union, distributed
in 75 countries worldwide, and has accumulated more than 212,000
human treatments to date, to reduce "cytokine storm" and other
toxins that can cause organ failure. The DrugSorb™-ATR
antithrombotic removal system, based on the same polymer technology
as CytoSorb, has received two U.S. FDA Breakthrough Device
Designations to remove two separate blood thinners during
cardiothoracic surgery, including ticagrelor and the direct oral
anticoagulants (DOAC) apixaban and rivaroxaban, and is undergoing
pivotal clinical studies. For more information, please visit the
Company’s websites
at www.cytosorbents.com and www.cytosorb.com or
follow us on Facebook and Twitter.
Forward-Looking Statements
This press release includes forward-looking
statements intended to qualify for the safe harbor from liability
established by the Private Securities Litigation Reform Act of
1995. These forward-looking statements include, but are not limited
to, statements about our plans, objectives, future targets and
outlooks for our business, statements about potential exposures
resulting from our cash positions, representations and contentions,
and are not historical facts and typically are identified by use of
terms such as “may,” “should,” “could,” “expect,” “plan,”
“anticipate,” “believe,” “estimate,” “predict,” “potential,”
“continue” and similar words, although some forward-looking
statements are expressed differently. You should be aware that the
forward-looking statements in this press release represent
management’s current judgment and expectations, but our actual
results, events and performance could differ materially from those
in the forward-looking statements. Factors which could cause or
contribute to such differences include, but are not limited to, the
risks discussed in our Annual Report on Form 10-K, filed with the
SEC on March 9, 2023, as updated by the risks reported in our
Quarterly Reports on Form 10-Q, and in the press releases and other
communications to shareholders issued by us from time to time which
attempt to advise interested parties of the risks and factors which
may affect our business. We caution you not to place undue reliance
upon any such forward-looking statements. We undertake no
obligation to publicly update or revise any forward-looking
statements, whether as a result of new information, future events,
or otherwise, other than as required under the Federal securities
laws.
CytoSorbents Contact: Kathleen Bloch(732)
398-5429 kbloch@cytosorbents.com
CytoSorbents (NASDAQ:CTSO)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
CytoSorbents (NASDAQ:CTSO)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024